Accelerating Orphan Drug Development

OCTOBER 2019
IMPORTANT NOTICE AND DISCLAIMER

This presentation has been prepared by Centogene B.V. or a successor entity (the “Company”) and is made for informational purposes only and does not
constitute an offer to sell or a solicitation of an offer to buy securities, nor shall there be any sale of any of securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. The information set forth herein
does not purport to be complete or to contain all of the information you may desire. Statements contained herein are made as of the date of this presentation
unless stated otherwise, and neither the delivery of this presentation at any time, nor any sale of securities, shall under any circumstances create an implication
that the information contained herein is correct as of any time after such date or that information will be updated or revised to reflect information that subsequently
becomes available or changes occurring after the date hereof.

Certain information contained in this presentation relates to or is based on studies, publications, surveys and other data obtained from third-party sources and the
Company's own internal estimates and research. While the Company believes these third-party sources to be reliable as of the date of this presentation, it has not
independently verified, and makes no representation as to the adequacy, fairness, accuracy or completeness of, any information obtained from third-party
sources. In addition, all of the market data included in this presentation involves a number of assumptions and limitations, and there can be no guarantee as to the
accuracy or reliability of such assumptions. Finally, while the Company believes its own internal research is reliable, such research has not been verified by any
independent source.

This presentation contains statements that constitute ‘forward looking statements’ as that term is defined in the United States Private Securities Litigation Reform
Act of 1995, including statements that express the Company’s opinions, expectations, beliefs, plans, objectives, assumptions or projections regarding future
events or future results, in contrast with statements that reflect historical facts. Examples include discussion of our strategies, financing plans, growth opportunities
and market growth. In some cases, you can identify such forward-looking statements by terminology such as “anticipate,” “intend,” “believe,” “estimate,” “plan,”
“seek,” “project” or “expect,” “may,” “will,” “would,” “could” or “should,” the negative of these terms or similar expressions. Forward looking statements are based
on management’s current beliefs and assumptions and on information currently available to the Company. However, these forward-looking statements are not a
guarantee of our performance, and you should not place undue reliance on such statements. Forward-looking statements are subject to many risks, uncertainties
and other variable circumstances, such as negative worldwide economic conditions and ongoing instability and volatility in the worldwide financial markets,
possible changes in current and proposed legislation, regulations and governmental policies, pressures from increasing competition and consolidation in our
industry, the expense and uncertainty of regulatory approval, including from the U.S. Food and Drug Administration, our reliance on third parties and collaboration
partners, including our ability to manage growth and enter into new client relationships, our dependency on the rare disease industry, our ability to manage
international expansion, our reliance on key personnel, our reliance on intellectual property protection, fluctuations of our operating results due to the effect of
exchange rates or other factors. Such risks and uncertainties may cause the statements to be inaccurate and readers are cautioned not to place undue reliance
on such statements. Many of these risks are outside of the Company’s control and could cause its actual results to differ materially from those it thought would
occur. The forward-looking statements included in this presentation are made only as of the date hereof. The Company does not undertake, and specifically
declines, any obligation to update any such statements or to publicly announce the results of any revisions to any such statements to reflect future events or
developments.

We have filed a registration statement on Form F-1 (File No. 333-234177) (as amended, the “Registration Statement”) with the SEC for the offering to which this
communication relates. Before you invest, you should read the Registration Statement, the preliminary prospectus included within the Registration Statement
(including the risk factors set forth therein) and the other documents we have filed with the SEC for more complete information about us and this offering. You may
get these documents by visiting EDGAR on the SEC website at www.sec.gov. Alternatively, we, the underwriters or any dealer participating in the offering will
arrange to send you the prospectus if you request it by contacting: SVB Leerink LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston,
MA 02110, by telephone at (800) 808-7525, ext. 6132 or by email at syndicate@svbleerink.com; or Evercore Group L.L.C., Attention: Equity Capital Markets, 55
East 52nd Street, 36th Floor, New York, NY 10055, by telephone at 1-888-474-0200 or by e-mail at: ecm.prospectus@evercore.com.

2
Our Mission

We aim to improve the diagnosis and treatment of rare diseases by

unlocking critical knowledge that will accelerate drug development

and guide patient stratification, identification and monitoring

4
Centogene: The Rare Disease Company
Company Snapshot

• Founded in 2006 by Prof. Arndt Rolfs
• Headquartered in Rostock, Germany
• Other locations include Cambridge
(MA), Berlin, Boston, Vienna, Dubai
and Delhi
• 400+ employees
• Over 35 global biopharma partners
• Approximately €22M in revenue for
the first half of 2019, compared to
€17M for the same period in 2018

Investment Highlights

 Complementary business model that leverages expertise in clinical diagnostics to further our proprietary platform which
provides valuable insights to us and our biopharma partners

 10 commercialized proprietary biomarkers for 8 rare diseases, with over 30 additional biomarkers in research and
development

 Our proprietary data repository with epidemiologic, phenotypic and genetic, or multi-omic, data from over 450,000 patients
from over 115 countries

 Provide solutions to biopharma partners for drug discovery/development, from identification and into commercialization

 Broad diagnostic testing portfolio covering over 6,500 genes

5
Unmet Needs in Rare Diseases

5,600 identified Only ~230 FDA 5-7 years on 30% of rare

rare hereditary approved average to disease patients
diseases treatments for diagnose will not see their
rare diseases 5th birthday

Rare disease drug sales expected to be >$240B by 2024

Revolutionizing services to the orphan drug market through the integration of

diagnostic testing, informatics, biomarkers and interpretation of big data

Source: National Organization for Rare Disorders (NORD) 6

Highly Complementary Business Model Based on Proprietary
Platform

7
 Strengths of Centogene’s Platform in Supporting Rare Disease
Drug Development
Access to and Identification of Patients

Visible patient population

In a given rare disease

• Uncovering the rare disease patient population, with multi-omic data from over 450,000 patients and a biobank
Hidden patient population
Non-canonical and mostly oligo-
which holds biomaterials of these patients
symptomatic manifestation
• Expedite treatment of patients through early diagnosis with expertise, multi-level data and network of over
33,000 physicians
ADDED VALUE FOR PAT IENT S AND
BIOPHARMA COMPANIES
• Economically and medically efficient patient identification with biomarkers
(reducing diagnostic odyssey)

Holistic and Ethnically Diversified Data

• Capture full ethnic and hereditary drivers of disease with patients from over 115 countries

• Include proteomic and metabolomic data, with over 10 million unique variants and over 3,500 diseases-
associated phenotypes

• Fully curated clinical information to supplement genetic data, covering 12 therapeutic areas, which include over
3,100 diseases

• Well-known databases (ClinVar / HGMD) have limited utility

Disease Monitoring

• Improved treatment by individualized dosing (precision medicine) based on biomarkers, with 10 biomarkers
commercialized and over 30 biomarkers under development

• Support in demonstrating efficacy for drug regulatory approval – e.g. A paper published in June 2019 in
further confirmed that Lyso-Gb1 has the potential to be used as an accurate biomarker for monitoring children
suffering from Gaucher disease

Accelerate drug development and commercialization:

 Accelerates clinical trial recruitment  Deepens understanding market
 Optimizes trial design and dose titration  Increases market traction
8
Value Creation through Centogene’s Platform

Value for Biopharma Industry Value for patients

Biomarker • Developing biomarkers for high throughput Early • Expedited treatment through
Development patient testing and provide the ability to monitor Diagnosis early diagnosis
patients
• Support in demonstrating efficacy for regulatory
approval

Development • Expedited drug screening during discovery Access to • Connecting patients and
Therapies physicians to currently available
Acceleration • Leverage existing CentoMD database &
repository to identify patients and aid study treatments and also future
enrollment therapies

Patient • Utilize biomarker to accelerate patient Personalized • Ability to monitor patient’s

Identification identification to accelerate commercial adoption Medicine disease state, allowing for
via individualized dosing and
− Combing through existing database optimal patient outcome
− High throughput testing of new patients
through the existing network of physicians

9
Valuable Solutions for Our Biopharma Partners

Drug Discovery Pre-clinical / Clinical Development Commercialization

Preclinical Clinical
• Full understanding of the • Identifying patients for trials • Identifying additional patients • Identifying patients who will benefit
rare disease trials
Challenges • Testing the efficacy molecule • Continuous monitoring of patients
• Identifying the right with a sensitive and specific • Monitoring to demonstrate
target molecules readout patient response to drug

High Throughput Risk

In Vitro Molecular Screening
Centogene • Provide knowledge
Solutions • Delivering innovative patient derived
samples and biomarker screening
technology to expedite drug
screening
Epidemiological Study
• Leverage existing CentoMD
database to ID patients who exhibit
selected symptoms and aid in study
site enrollment
Biomarker Development
• Utilize metabolomics/proteomics
approach to screen patients/access
specific cohorts to feed into
biopharma sponsored biomarker
development programs
Population Testing
• Support patient ID by conducting
biochemical/genetic analyses on
samples from clinical study
• Develop study protocol

Key Partners

 Targeted development  Improved treatment

 De-risked development outcome
Goals
 Lower cost  Market traction
 Faster time to market

10
Transition of Biopharma Contracts from Fixed Fee to
Milestone-Based Payments
2015
• Fixed annual fee for unlimited number
of diagnostic tests for Fabry disease,
Gaucher disease and Hunter
syndrome to enhance early diagnosis
of patients
• Additional service-based payments
related to regulatory and diagnostic
sequencing activities
• Conduct extensive epidemiological
study to gain insights into HAE and
support clinical development efforts
(new agreements in 2018)
• Biomarker validation separately
sponsored by Shire
Preclinical
2019 2018
2018
• Inital fixed fee for access to Centogene’s
knowlege and know-how
• Additional fees for patient recruitment and
genotyping, operational milestones for
acceleration and completion of project,
and commercial milestones based on
regulatory and commercial success of the
Denali drug
• Collaboration for global, early
identification and recruitment of LRRK2
positive Parkinson‘s disease patients
• Use CentoCard and extensive network
with centers of excellence to accelerate
enrollment of patients into Denali‘s clinical
study and facilitate the drug development
process
2018 2018 2017
11
Comprehensive Suite of Diagnostic Solutions

Centogene offers the broadest diagnostic portfolio with over 10,000 tests
covering >6,500 genes

Up to 30 June 2019

12
Database Expansion – CentoCard, Simple Logistic Solution

 CE-marked

 Stable for 10+ years

 Ship via regular mail

 Available in 30+
languages

 Barcode for tracking

 Simple, efficient storage

 Contains consent to
retest biomaterial

13
Continued Expansion of Platform and Repository

Diagnostics Segment Orders by Technology (Jan 1, 2016

Approximate Order Requests 2016 to 2019 H1 to Aug 31, 2019)
120,000
Biochemistry and Others
6%
105,300
Sanger
100,000 Genetics
25%

81,600 83,000
NIPT
80,000 22%
57,400

62,500
60,000
56,900
60,800 46,900
29,800 WGS
40,000 3%
27,500
Panels
47,900 16%
20,000
32,700 WES
26,100 28%
20,800 19,400

0
2016 2017 2018 2018 H1 2019 H1

Diagnostics Business Pharmaceutical Business

14
Continued Expansion of Platform and Repository

Number of Biopharma Partners and Geographical Distribution of Source

Diseases Covered by Collaborations Patient Data Patients by Therapeutic Area

40 Malformation
and retardation Hematological
APAC 8% 1%
NAMER 3%
35 34 3%
32 Tumoral
16%
30
30 28 Europe Metabolic
42%
51%
LATAM Liver, kidney and
endocrinological
25 17% 5%
22

20 19 Vascular
1%
17
Cardiological
15 and lung
2%
Bone, skin and
11 immune
5%
10
MENA
Ear, nose and
26% throat Neurological
5 1% Ophthalmological 17%
2%

0
2016 2017 2018 2019 H1
No. of Pharmecutical Partners Disorder/Genes Covered

Up to 31 August 2019

15
 CentoMD 5.5 Comparison with HGMD and ClinVar

Total Genetic Variants

12,000,000
10,000,000
8,000,000
6,000,000
4,000,000
2,000,000
0
CentoMD 5.5 HGMD Pro ClinVar
2019.1 2019.09.16

N= 32,125 Shared Variants

13% Discordantly classified

N= 159,149 Shared Variants

9% Discordantly classified

Based on the variants in CentoMD 5.5 (released in September 2019), a comparison against the list of variants in
other industry databases such as ClinVar (version ClinVar 2019, September 2019) and HGMD Pro (version
HGMD Pro 2019.1, January 2019) shows that of the shared variants among CentoMD 5.5, ClinVar and HGMD Pro,
approximately 9% and approximately 13% of such shared variants in ClinVar and HGMD Pro, respectively, are
discordantly classified.
16
Artificial Intelligence Drives Rapid Biomarker Development

Fully automated biomarker candidate selection

Processing of data Perform data analytics / Compound Benefits

artificial intelligence
(Repetitive process)
ranking and
visualization • Time saving (from 6
months manually to 2
days)
• Detection of combined
biomarkers
• Performing virtual
experiment designs

Application of expert Aggregation of

filters models and results
from each run

17
Biomarker Development Programs
Proof-of- Validation Validation
Disease Target Dev. Patient Access Tech. Validation Concept Stage I Stage II Market
Gaucher Disease (Lyso-Gb1)

Gaucher (Gb1 -GLucosylCeramides in DBS)

Fabry Disease (Lyso-Gb3)

Farber Disease

Niemann-Pick Type C Disease (Lyso-509)

Niemann Pick (Type A/B (Lyso-509 & Lyso-465)

Cystic fibrosis (C26)

Hereditary Angiodema (HAE) – Proteomics

HAE – high molecular weight kininogen

AADC (3-OMD)

Hunter (MPS II)

Morquio A (MPS IVA)

Hereditary Angioedema (metabolite)

Duchenne Muscular (Dystrophy)

MLD (ARSA biomarker)

Pompe

Amyloidosis (TTR-FAP)

Alpha-manosidase

Tyrosinemia Type 1
Selected List as of 31 August 2019
For further information, please visit www.clinicaltrials.gov
NCL 2

18
Case Study: Lyso-Gb1 Biomarker in Gaucher Disease

High sensitivity and specificity for diagnosis and monitoring of Gaucher disease

Level of Biomarker
Disease manifestation threshold Therapeutic
Window

Time

Easier patient identification

Ability to monitor disease
100% sensitivity and 99.9% specificity of
Potential to demonstrate drug efficacy and
biomarker leading to
guide individualized treatment
100% accuracy in patient identification*

*Based on the combination of biomarker and genetic confirmatory test and on the definition of the cut-off of 12ng/ml Lyso-Gb1
Source: Rolfs et. al 2013
19
Key Performance Indicators Driving Growth

• Over 35 biopharma partners for over 30 different rare diseases

Biopharma • Approximately €9M in biopharma partnership revenue in the first half of 2019
which shows 39% growth from the same period in 2018
Revenue

• 62,500 test requests in the first half of 2019 which shows 33% growth from the
same period in 2018
Diagnostics
• €13M in diagnostics revenue in the first half of 2019 which shows 23% growth
from the same period in 2018

• Comprehensive multi-omic data with over 2 billion data points from more than
Data

450,000 patients
Data Repository
• Covers a substantial majority of ethnicities, sourcing data from patients in over
115 countries

• We have developed 10 commercialized biomarkers which enable us to provide

Pipeline

Partnerships / services to our pharma partners in all phases of drug development

Biomarker
• Our pipeline consists of over 30 biomarkers under development, covering AADC
Development deficiency, Cystic Fibrosis, Fabry disease, and others

20
Financial Information
Million €

Revenue by Segment Adjusted EBITDA by Segment

45 16 110%
40
40 14
90%
35 12
32
10 70%
30 28 23
8
25
22 50%
18
6
20 15
17
4 30%
15 13

11 2
10 10%
17
14 0
12
5 9
6 (2) -10%
0 2016 FY 2017 FY 2018 FY 2018 H1 2019 H1
2016 FY 2017 FY 2018 FY 2018 H1 2019 H1 Pharma EBITDA Diagnostics EBITDA
Pharma Revenues Diagnostic Revenues Pharma EBITDA % Diagnostics EBITDA %

Adjusted segment EBITDA excludes corporate expenses (i.e. expenses related to group functions such as communications, human resources,
finance, legal, research and development and other supporting activities), and also excludes depreciation and amortization, interest and similar
income and expenses and share-based payment expenses.

21
Financial Summary

• €40M in revenue in 2018, €22M in revenue for the first half of 2019; €17M in revenue for the same period
in 2018

• €3.6M in cash as of June 30, 2019

• €20M in debt outstanding as of June 30, 2019

• Sales and Leaseback transaction for the Rostock Headquarter building completed in September 2019 for
€24M

• Investors include TVM Capital, Deutsche Private Equity and CareVentures

• Insider commitment of $30M

22
The Rare Disease Company

23